Core Insights - The company has shifted its business development strategy from acquiring on-market specialty products to focusing on oncology therapeutics due to increased competition and rising acquisition costs [1] - The integration of the Spectrum acquisition is complete, enhancing operational efficiencies by consolidating regulatory, distribution, and manufacturing functions under a single Assertio label [1] - Management has decided to deprioritize further investment in SYMPAZAN, redirecting resources towards higher-growth oncology opportunities [1] Financial Performance - Q4 2025 performance was strategically impacted by a 'sell-in' of Robodon in Q3 to ensure patient supply during the transition to a new consolidated commercial label [1] - The commercial platform is being optimized to maximize cash flow from 'tail assets' like Indocin while focusing on the growth and life cycle management of Robodon [1]